Fulcrum Therapeutics disclosed a major reorganization after discontinuing development of its sickle cell disease program, pociredir. Following FDA concerns raised in a meeting about the benefit-risk profile, Fulcrum said it sees no viable regulatory path forward and is now pursuing strategic alternatives. The company moved quickly to cut costs, with an SEC filing describing layoffs affecting most of its workforce. Fulcrum stated that the FDA concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, citing unexpectedly high secondary hematologic malignancy rates observed with Ipsen’s PRC2 inhibitor Tazverik, which Ipsen pulled globally in March. The decision has immediate market implications: Fulcrum’s stock fell sharply as investors absorbed the loss of its lead asset and the near-term reduction in operating capacity. For the broader field, the case reinforces how safety signals in related PRC2 inhibitor contexts can rapidly change development trajectories across indications.